Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12572603 | 0.86 | CYP1A2 (0.44) | CYP1A2PKMPTK2BL3MBTL1ALDH1A1 | |
| SCHEMBL22454078 | 0.83 | CYP1A2 (0.43) | CYP1A2PKMPTK2BL3MBTL1ALDH1A1 | |
| SCHEMBL1138743 | 0.83 | EPHX1 (0.44) | CYP1A2PKMPTK2BL3MBTL1ALDH1A1 | |
| SCHEMBL31066656 | 0.81 | CYP1A2 (0.41) | CYP1A2PKMPTK2BL3MBTL1ALDH1A1 | |
| SCHEMBL3648521 | 0.81 | CRBN (0.48) | CYP1A2PKMPTK2BL3MBTL1ALDH1A1 | |
| SCHEMBL14997672 | 0.81 | RIPK1 (0.41) | CYP1A2PKMPTK2BL3MBTL1ALDH1A1 | |
| SCHEMBL13713522 | 0.78 | CYP1A2 (0.40) | CYP1A2PKMPTK2BL3MBTL1ALDH1A1 | |
| SCHEMBL20970392 | 0.78 | CYP1A2 (0.40) | CYP1A2PKMPTK2BL3MBTL1ALDH1A1 | |
| SCHEMBL6970957 | 0.78 | CYP1A2 (0.40) | CYP1A2PKMPTK2BL3MBTL1ALDH1A1 | |
| SCHEMBL14191707 | 0.78 | CYP1A2 (0.40) | CYP1A2PKMPTK2BL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119894533-A | Methods and compositions for activating, modulating and regulating weight loss and therapeutic uses thereof | 科吉恩治疗股份有限公司 | 2025-04-25 | — | — | CN | disclosed |
| US-20240294491-A1 | SALT OF HETEROCYCLIC COMPOUND WITH ANTI-MALARIA ACTIVITY, AND CRYSTALS THEREOF | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2024-09-05 | — | — | US | disclosed |
| EP-4342889-A1 | SALT OF HETEROCYCLIC COMPOUND WITH ANTI-MALARIA ACTIVITY, AND CRYSTALS THEREOF | Eisai R&D Management Co., Ltd. (JP) | 2024-03-27 | — | — | EP | disclosed |
| US-11858940-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| CN-108028428-B | Non-aqueous fluoride salts, solutions and uses thereof | 加州理工学院 | 2022-02-18 | — | — | CN | disclosed |
| US-11066416-B2 | Rapafucin derivative compounds and methods of use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-07-20 | — | — | US | disclosed |
| WO-2020031796-A1 | LUBRICATION METHOD | ＪＸＴＧエネルギー株式会社 | 2020-02-13 | — | — | WO | disclosed |
| US-20200040004-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RAPAFUSYN PHARMACEUTICALS, INC. | 2020-02-06 | — | — | US | disclosed |
| EP-3239238-A1 | THERMOPLASTIC RESIN COMPOSITION AND MOLDED ARTICLE CONTAINING SAME | Mitsubishi Gas Chemical Company, Inc. (JP) | 2017-11-01 | — | — | EP | disclosed |
| EP-2067821-A1 | POLYACETAL RESIN COMPOSITION | Polyplastics Co., Ltd. (JP) | 2009-06-10 | — | — | EP | disclosed |
| US-20040053923-A1 | Novel isoindole derivatives | BANYU PHARMACEUTICAL CO., LTD. | 2004-03-18 | — | — | US | disclosed |
| US-20030194646-A1 | Mono-, di-, and triazaporphyrin compounds optionally in the form of a metal or metalloid complex | MITSUI CHEMICALS, INC. (JP) | 2003-10-16 | — | — | US | disclosed |
| US-6627288-B1 | Optical recording medium and porphycene compound | MITSUI CHEMICALS, INC. (JP) | 2003-09-30 | — | — | US | disclosed |
| US-6608098-B1 | Diabetes or obesity, 2-(4-(3-isopropyl-2,5-dioxo-2,3-dihydro-1H-pyrrolo(2,1-a) isoindol-9(5H)-yl)phenoxy)-N-propylacetamide | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2003-08-19 | — | — | US | disclosed |
| US-20030091931-A1 | Benzbisazole compound and optical recording medium containing the compound | MITSUI CHEMICALS, INC. (JP) | 2003-05-15 | — | — | US | disclosed |
| EP-1262966-A2 | Optical recording medium and novel azaporphyrin compound | Mitsui Chemicals, Inc. (JP) | 2002-12-04 | — | — | EP | disclosed |
| EP-1247655-A1 | OPTICAL RECORDING MEDIUM AND NOVEL AZAPORPHYRIN COMPOUNDS | Mitsui Chemicals, Inc. (JP) | 2002-10-09 | — | — | EP | disclosed |
| EP-1245571-A1 | BENZBISAZOLE COMPOUND AND OPTICAL RECORDING MEDIUM CONTAINING THE COMPOUND | Mitsui Chemicals, Inc. (JP) | 2002-10-02 | — | — | EP | disclosed |
| EP-1207161-A1 | NOVEL ISOINDOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-05-22 | — | — | EP | disclosed |
| EP-1180765-A1 | Optical recording medium and porphycene compound | Mitsui Chemicals, Inc. (JP) | 2002-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11066416-B2 | Rapafucin derivative compounds and methods of use thereof | RICTOR, FKBP14, MTOR | CYP1A2 4052/4885PKM 4395/4885PTK2B 1883/4885 |
| US-20200040004-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | CYP1A2 4052/4885PKM 4395/4885PTK2B 1883/4885 |
| US-20240294491-A1 | SALT OF HETEROCYCLIC COMPOUND WITH ANTI-MALARIA ACTIVITY, AND CRYSTALS THEREOF | REN, RCC1, LSS | CYP1A2 1411/4885PKM 1961/4885PTK2B 3495/4885 |
| US-20030091931-A1 | Benzbisazole compound and optical recording medium containing the compound | DAO, CACNA1I, KCNB2 | CYP1A2 308/4885PKM 1951/4885PTK2B 894/4885 |
| US-11858940-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | LRRK2, ADRM1, CRBN | CYP1A2 4779/4885PKM 2397/4885PTK2B 993/4885 |
| US-20040053923-A1 | Novel isoindole derivatives | GPR119, SLC5A2, SLC5A1 | CYP1A2 68/4885PKM 2376/4885PTK2B 1859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.